T-ALLCD7-CAR T

Bernice L Z Oh1,2, Noriko Shimasaki2, Elaine Coustan-Smith2

  • 1Viva-University Children's Cancer Center, Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, National University Health System, Singapore, Singapore.

Nature medicine
|September 3, 2024
PubMed
概括

化学抗原受体 (CAR) 向CD7的T细胞对复发性或耐火性T细胞急性淋巴细胞白血病 (T-ALL) 有希望. 这种疗法实现了高缓解率与可控毒性,为难以治疗的T-ALL提供了新的治疗途径.